A murine model of xenotransplantation of human glioblastoma with imunosupression by orogastric cyclosporin

Alexandre M. Cunha1,2, Fernanda S. Nascimento1, Jane C.O.F. Amaral3, Sandra Konig3, Crhistina M. Takiya4, Vivaldo M. Neto3,5, Eduardo Rocha6, Jorge P.B.M. Souza1

ABSTRACT
Several animal experimental models have been used in the study of malignant gliomas. The objective of the study was to test the efficacy of a simple, reproducible and low cost animal model, using human cells of glioblastoma multiforme (GBM) xenotransplanted in subcutaneous tissue of Wistar rats, immunosuppressed with cyclosporin given by orogastric administration, controlled by nonimmunosuppressed rats. The animals were sacrificed at weekly intervals and we have observed gradual growth of tumor in the immunosuppressed group. The average tumor volume throughout the experiment was 4.38 cm$^3$ in the immunosuppressed group, and 0.27 cm$^3$ in the control one (p<0.001). Tumors showed histopathological hallmarks of GBM and retained its glial identity verified by GFAP and vimentin immunoreaction. Immunosuppression of rats with cyclosporin was efficient in allowing the development of human glioblastoma cells in subcutaneous tissues. The model has demonstrated the maintenance of most of the histopathological characteristics of human glioblastoma in an heterotopic site and might by considered in research of molecular and proliferative pathways of malignant gliomas.

Key words: animal model, Wistar rats, cyclosporin, glioblastoma, xenotransplant.

RESUMO
Vários modelos animais têm sido avaliados no estudo dos gliomas e até o momento nenhum pode ser considerado ideal. O objetivo deste trabalho é verificar a eficácia de um modelo animal simples, reprodutível e de baixo custo. Utilizamos células humanas de glioblastoma multiforme (GBM) xenotransplantadas em ratos Wistar, submetidos a imunossupressão com ciclosporina administrada por via orogástrica. Células tumorais foram implantadas no tecido subcutâneo dos ratos imunossuprimidos com ratos não imunossuprimidos. O modelo动物模型显示了在异位位置保持人类胶质瘤的大部分组织病理学特征，并可用于研究胶质瘤的分子和增殖途径。

Key words: animal model, Wistar rats, cyclosporin, glioblastoma, xenotransplant.

1Division of Neurosurgery, Department of Surgery, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro RJ, Brazil; 2Division of Neurosurgery, Department of Surgical Specialties, Pedro Ernesto University Hospital, State University of Rio de Janeiro, Rio de Janeiro RJ, Brazil; 3Department of Anatomy, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro RJ, Brazil; 4Department of Histology and Embriology, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro RJ, Brazil; 5National Institute for Translational Neuroscience, Ministry of Science and Technology, Brazil; 6Division of Nephrology, Department of Internal Medicine, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro RJ, Brazil.
Xenotransplantation: murine model
Cunha et al.

Glioblastoma multiforme (GBM) is the most frequent primary brain tumor and is classified by the World Health Organization (WHO) in the group of diffusely infiltrative astrocytomas, representing the most malignant subtype of them\textsuperscript{1-9}. Understanding the mechanisms of angiogenesis, cellular migration and proliferative pathways might improve therapeutic development for the treatment of GBM\textsuperscript{10-12}. Scientific knowledge of the biology of the gliomas has been evolving with the use of animal models\textsuperscript{13}.

An ideal animal model for the study of gliomas must have some defined characteristics: growth rate and malignancy characteristics of the tumor should be reproducible; the time of the tumor induction should be relatively short and the survival time should be standardized; the tumor should present intraparenchymal growth that simulates glioma, showing invasion, neovascularity and no encapsulation; the tumor should grow well in culture and must be safe for the laboratorial handling; and cheap and small species must be preferable\textsuperscript{14,15}. Although many animal models are available, none of them fills all above the described characteristics\textsuperscript{14,15}.

The model of orthotopic xenotransplantation with human tumor cells in anergic or imunosuppressed animals is the best way to simulate the growth of human gliomas\textsuperscript{16}. The models of heterotopic transplant outside the central nervous system are frequently used, and the subcutaneous xenografts are useful and reproducible models that allow the study of molecular biology and genetic alterations in GBM\textsuperscript{17}.

These models of subcutaneous implantation allow a fast tumor growth and an easy evaluation of the size and volume of the tumor, without need of the animal’s sacrifice. Moreover, no major histopathological difference has been demonstrated between the tumors implanted in subcutaneous and in cerebral tissue\textsuperscript{18}. Because of difference in the pattern and vascular architecture between the models of cerebral and subcutaneous implantation, and also of the absence of blood-brain barrier in the subcutaneous models, care has to be taken in extrapolating the results of studies with subcutaneous models to human brain gliomas\textsuperscript{19,20}.

The main objective of the present work was to verify the utility of an experimental model of human glioblastoma cells xenotransplantation in subcutaneous tissue of Wistar rats, imunosuppressed with cyclosporine given by orogastric administration.

**METHOD**

**Tumor cells**

Tumour sample (GBM-95) was obtained from a patient with GBM treated at the Neurosurgery Division from University Hospital Clementino Fraga Filho and experimental use was approved by Ethical Committee from Brazilian Ministry of Health. The protocol of this study was also approved by the Committee of Ethics in Animal Researches of Department of Surgery of Federal University of Rio de Janeiro. Microscopically dissected tumor was transferred to tissue culture flasks containing culture me-

---

**Fig 1.** [A] Tumor cell culture of GBM-95 lineage used in the xenotransplantation. Scale bar: 150 µm. [B] Photomicrographies of Gbm 95 cells after GFAP immunoreaction (red) showing the predominant punctuate pattern, and [C] vimentin immunoreaction (green) showing the fibrillar pattern. Cells were stained with 40,6-diamidino-2-phenylindole for nuclei visualization (blue). Scale bar: 20 µm.
The rats were sacrificed at weekly intervals, using the same anesthetic protocol, from the end of the first to the fourth week of experiment. Five rats were sacrificed each week in the immunosuppressed group and in the control group three rats were sacrificed at the end of first week, and four at the end of the next three weeks.

Tumor mass was identified, dissected, removed in bloc, measured and placed in 10% neutral buffered formalin. When no lesion was identified, subcutaneous tissue was isolated and kept in the same formalin solution.

Tumor volume was estimated by multiplying anterior-posterior, lateral-lateral and superior-inferior measures of the lesion, and the result divided by two.

After resection of the flank tumor, abdomen and thoracic cavities were inspected and kidneys, liver, spleen and lungs were removed for macroscopic metastatic verification.

Histopathologic analysis

Tissues removed from the animals were maintained in the 10% neutral buffered formalin for 96 hours. Afterwards, specimens were processed to hematoxylin and eosin (HE) staining and final neuropathological analysis was done in order to verify the presence of the glial component of the tumor and histopathological characteristics.

Immunohistochemistry

Biotin-streptavidin-peroxidase immunohistochemistry was performed in 3-4 mm thickness paraffin tumor sections. Sections were immunostained with anti-GFAP and anti-vimentin monoclonal primary antibodies (Dako, CA). The universal immunostaining system streptavidin-peroxidase kit (Coulter, Fullerton, CA) was used to develop the reaction. Hematoxylin was used to stain and counterstain paraffin tumor sections and mounted with Permount. The primary antibody was omitted to provide negative controls.

Statistical analysis

Statistical analyses of the tumor volume differences between the two groups were made with t-test and Mann-Whitney rank sum test by Sigmastat program, with a statistical significance of 5% (p<0.05).

RESULTS

Immunocytochemistry

The cells of GBM 95 are positive to both GFAP and vimentin. In vimentin immunoreaction a cytoplasmatic fibrillary pattern was observed, while in GFAP the cytoplasm staining had a more punctuated distribution (Fig 1B and 1C). These data show that GBM95 cells retaining its astroglial identity, also after many passages in culture.
Macroscopy

In the non-immunosuppressed samples there was no measurable tumor growth in the first week. By the end of the second week there was tumor in all rats. At the third week, two animals had a small tumor and two others did not have any lesion. At the fourth week none of the rats had macroscopic tumor.

In the immunosuppressed group we have observed tumor in four of the five rats in the first week. We have verified presence of tumor in all five animals in the following weeks with progressive increase of mass volume toward the fourth week. At the fourth week all the rats had large lesions with evident central necrosis. The lesions were well circumscribed without infiltration of adjacent tissues in both groups - immunosuppressed (Fig 2A and 2B), and control one.

The tumor volume measures have showed significant difference between the two groups in all experiment. The rate of the tumor growth was larger in the immunosuppressed group throughout all the four weeks. Tumor volume average in the immunosuppressed group was 4.38 cm$^3$ and in the control group was 0.27 cm$^3$. Comparing these data of the two groups throughout all the experiment, regardless the timing, there was a significant statistical difference between them ($p<0.001$).

A progressive increase of the tumor volume was verified in both groups until the third week. At the fourth week there was regression of tumor in the control group and marked growth of tumor volume in the immunosup-


Fig 3. Average tumor volume in the both groups.
pressed group, with significant statistical difference between de two groups (p=0.0059) (Fig 3).

We have not detected any metastasis to lungs, spleen, liver or kidneys in none of the animals.

**Histopathology**

Histopathological analysis revealed presence of glial neoplasia in all the removed lesions. The tumors were characterized by elongated cells on a fibrillar background, with mitosis and nuclear pleomorphism (Fig 2C). They were well vascularized and inflammatory cells were seen at the periphery of the lesions. We observed the presence of central necrosis, including pseudopalisading necrosis, more evident in the largest lesions at the fourth week (Fig 2D).

There was no evidence of neoplastic tissue in the subcutaneous implantation area from animals that did not have macroscopic tumor.

**Immunohistochemistry**

The immunohistochemistry are strongly positive for GFAP and vimentin in lesions of both groups, demonstrating the glial nature of the developed tumors in rats (Fig 2E and 2F).

**DISCUSSION**

Animal models are a fundamental step in the study of neoplasias and xenotransplantation have been used with several configurations for human GBM. Our design had the objective of testing a simple and practical experimental model, using Wistar rats immunosuppressed with cyclosporin for GBM human cells implantation in the inguinal subcutaneous tissue.

Cyclosporin promotes immunosuppression through its highly selective ability to inhibit the activation of T cells, by means of the inhibition of the calcineurin, and is largely studied in organs transplantation in order to decrease the index of rejection. It has been demonstrated that cyclosporin inhibits the growth of murine glioma cells in vitro in dose dependent mechanism. Apoptosis of tumoral cells, when exposed to the cyclosporin, seems to be mediated by the gene p53.

Inhibition of the tumoral cell proliferation was not observed in our model as well as induction of apoptosis. Our results clearly demonstrated that cyclosporin immunosuppression was related to tumor growth. A possible explanation for these differences is the fact that we have used the drug in doses next to the same of ones for clinical utilization (5 mg/kg/day) through orogastric administration in opposite of direct cell exposition as in vitro studies.

Immunosupression of the animals receiving cyclosporin was clearly evident after observing GBM lesions in all the animals by the end of the fourth week, where as in the control group there was complete involution of the tumors. The difference of tumor volume between both immunosuppressed and control groups, by the end of the fourth week, was statistically significant (p=0.0059). Moreover, the rate of the tumor growth was larger in the immunosuppressed group throughout all the four weeks. Comparing the tumor volume of the two groups, there was a significant difference between them (p<0.001), showing that the cyclosporin administration was determinant for the tumor development.

Our results have been similar to a previous work, where human glioblastoma cells were transplanted into brain and ocular region of cyclosporin immunosuppressed rats, by daily intraperitoneal injections at a dose of 5 mg/kg. Xenotransplantation models of human glioblastoma multiforme in rats immunosuppressed with cyclosporin have also been used in the study of tumor invasion and in the development of new drugs, but we have found no articles in English literature where cyclosporin was given by orogastric route to the rats.

The occurrence of systemic metastasis of GBM is rare, and isolated cases have been described in literature. Therefore, these models are not adequate for the study of cellular migration, but they are useful in the study of proliferation.

We have verified the presence of histopathological characteristic aspects of human glioblastoma multiforme - hypercellularity, nuclear atypia, mitosis, abundant vascularization and necrosis, also with areas of pseudopalisading necrosis - that had been more intense at the fourth week. According to other studies, endothelial proliferation is not usually observed in these type of models.

In conclusion, the experimental model of human GBM xenotransplantation in subcutaneous tissues of Wistar rats immunosuppressed with orogastric given cyclosporin is a simple, efficient and low cost model that reproduces much of the profile of human glioblastoma. It should not be used as a model for study of the biology of migration, due to the different matrix for cell-to-cell and
cell-to-extracellular components interactions, but may contribute for future research in proliferative pathways of malignant glial tumors.

REFERENCES